Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

Maddalena Barba, Laura Pizzuti, Isabella Sperduti, Clara Natoli, Teresa Gamucci, Domenico Sergi, Luigi Di Lauro, Luca Moscetti, Fiorentino Izzo, Massimo Rinaldi, Lucia Mentuccia, Angela Vaccaro, Laura Iezzi, Antonino Grassadonia, Andrea Michelotti, Elisabetta Landucci, Letizia Perracchio, Edoardo Pescarmona, Franco Di Filippo, Antonio GiordanoMarcello Maugeri-Saccà, Patrizia Vici

Research output: Contribution to journalArticle

Abstract

Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1%, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95% CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings.

Original languageEnglish
Pages (from-to)986-991
Number of pages6
JournalJournal of Cellular Physiology
Volume231
Issue number5
DOIs
Publication statusPublished - May 1 2016

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Fingerprint Dive into the research topics of 'Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin'. Together they form a unique fingerprint.

  • Cite this

    Barba, M., Pizzuti, L., Sperduti, I., Natoli, C., Gamucci, T., Sergi, D., Di Lauro, L., Moscetti, L., Izzo, F., Rinaldi, M., Mentuccia, L., Vaccaro, A., Iezzi, L., Grassadonia, A., Michelotti, A., Landucci, E., Perracchio, L., Pescarmona, E., Di Filippo, F., ... Vici, P. (2016). Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. Journal of Cellular Physiology, 231(5), 986-991. https://doi.org/10.1002/jcp.25213